Two Decades of Research in Drug Delivery Systems for the Treatment of Diseases of the Posterior Segment of the Eye

Fialho SL , da Silva-Cunha A . New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Exp Ophthalmol, 2004; 32(6):626–632; doi: 10.1111/j.1442-9071.2004.00914.x

Fialho SL , Silva-Cunha A . Manufacturing techniques of biodegradable implants intended for intraocular application. Drug Deliv, 2005; 12(2):109–116; doi: 10.1080/10717540590921432

Gragoudas ES , Adamis AP , Cunningham ET Jr. , et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 2004; 351(27):2805–2816; doi: 10.1056/NEJMoa042760

Michels S , Rosenfeld PJ , Puliafito CA , et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, 2005; 112(6):1035–1047; doi: 10.1016/j.ophtha.2005.02.007

Rosenfeld PJ , Moshfeghi AA , Puliafito CA . Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging, 2005; 36(4):331–335.

Avery RL , Pieramici DJ , Rabena MD , et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology, 2006; 113(3):363–372.e5; doi: 10.1016/j.ophtha.2005.11.019

Rich RM , Rosenfeld PJ , Puliafito CA , et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina, 2006; 26(5):495–511; doi: 10.1097/01.iae.0000225766.75009.3a

El-Mollayess GM , Noureddine BN , Bashshur ZF . Bevacizumab and neovascular age related macular degeneration: Pathogenesis and treatment. Semin Ophthalmol, 2011; 26(3):69–76; doi: 10.3109/08820538.2010.545100

Ozturk BT , Kerimoglu H , Bozkurt B , et al. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther, 2011; 27(4):373–377; doi: 10.1089/jop.2010.0195

Zhang H , Liu ZL , Sun P , et al. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: Eighteen-month results of a prospective trial. J Ocul Pharmacol Ther, 2011; 27(6):615–621; doi: 10.1089/jop.2011.0050

Jonas JB , Kreissig I , Söfker A , et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol, 2003; 121(1):57–61.

Jonas JB , Kamppeter BA , Harder B , et al. Intravitreal triamcinolone acetonide for diabetic macular edema: A prospective, randomized study. J Ocul Pharmacol Ther, 2006; 22(3):200–207; doi: 10.1089/jop.2006.22.200

Baath J , Ells AL , Crichton A , et al. Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther, 2007; 23(3):304–310; doi: 10.1089/jop.2006.125

Martin DF , Parks DJ , Mellow SD , et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A Randomized Controlled Clinical Trial. Arch Ophthalmol, 1994; 112(12):1531–1539; doi: 10.1001/archopht.1994.01090240037023

U.S. Food and Drug Administration. Search Orphan Drug Designations and Approvals. Ganciclovir intravitreal implant. Marketing approved. 2006. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=86494 [Last accessed: July 3, 2024].

Azad R , Chandra P , Gupta R . The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol, 2007; 55(6):441–443; doi: 10.4103/0301-4738.3647

Spooner KL , Mhlanga CT , Hong TH , et al. The burden of neovascular age-related macular degeneration: A patient’s perspective. Clin Ophthalmol, 2018; 12:2483–2491; doi: 10.2147/OPTH.S185052

Fialho SL , Rêgo MB , Siqueira RC , et al. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res, 2006; 31(6):525–534; doi: 10.1080/02713680600719036

Fialho SL , Siqueira RC , Jorge R , et al. Biodegradable implants for ocular delivery of anti-inflammatory drug. J Drug Deliv Sci Technol, 2007; 17(1):93–97; doi: 10.1016/S1773-2247(07)50013-4

Siqueira RC , Dos Santos WF , Scott IU , et al. Neuroprotective effects of intravitreal triamcinolone acetonide and dexamethasone implant in rabbit retinas after pars plana vitrectomy and silicone oil injection. Retina, 2015; 35(2):364–370; doi: 10.1097/IAE.0000000000000284

Cunha RB , Siqueira RC , Messias A , et al. Safety and feasibility of a novel 25-gauge biodegradable implant of dexamethasone for treatment of macular edema associated with retinal vein occlusion: A phase I clinical trial. Retin Cases Brief Rep, 2018; 12(1):50–58; doi: 10.1097/ICB.0000000000000413

Saliba JB , Faraco AAG , Yoshida MI , et al. Development and characterization of an intraocular biodegradable polymer system containing cyclosporine-A for the treatment of posterior uveitis. Mat Res, 2008; 11(2):207–211; doi: 10.1590/S1516-14392008000200016

Saliba JB , Gomes CLG , Silva-Cunha A , et al. Development and validation of a high performance liquid chromatographic method for determination of cyclosporine-A from biodegradable intraocular implants. Quím Nova, 2011; 34(1):140–144; doi: 10.1590/S0100-40422011000100026

Saliba JB , Silva-Cunha A , Silva GR , et al. Characterization and in vitro release of cyclosporine-A from poly(D,L-lactide-co-glycolide implants obtained by solvent/extraction evaporation. Quím Nova, 2012; 35(4):723–727; doi: 10.1590/S0100-40422012000400013

de Almeida FP , Saliba JB , Ribeiro JA , et al. In vivo release and retinal toxicity of cyclosporine-loaded intravitreal device. Doc Ophthalmol, 2015; 131(3):207–214; doi: 10.1007/s10633-015-9520-z

Souza MC , Fialho SL , Souza PA , et al. Tacrolimus-loaded PLGA implants: In vivo release and ocular toxicity. Curr Eye Res, 2014; 39(1):99–102; doi: 10.3109/02713683.2013.819927

Gasparin F , Aguiar RG , Ioshimoto GL , et al. Pharmacokinetics, electrophysiological, and morphological effects of the intravitreal injection of mycophenolic acid in rabbits. J Ocul Pharmacol Ther, 2014; 30(6):502–511; doi: 10.1089/jop.2013.0236

Byrro RMD , de Oliveira GF , Rocha PC , et al. Determination of Mycophenolic acid in the vitreous humor using the HPLC-ESI-MS/MS method: Application of intraocular pharmacokinetics study in rabbit eyes with ophthalmic implantable device. J Pharm Biomed Anal, 2013; 84:30–35; doi: 10.1016/j.jpba.2013.05.030

Paiva MRB , Lage NA , Guerra MCA , et al. Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits’ eyes. Doc Ophthalmol, 2019; 138(1):3–19; doi: 10.1007/s10633-018-9664-8

Paiva MRB , Vasconcelos-Santos DV , Vieira LC , et al. Sirolimus-loaded intravitreal implant for effective treatment of experimental uveitis. AAPS PharmSciTech, 2021; 22(1):35; doi: 10.1208/s12249-020-01898-4

Solano AGR , Silva GR , Fialho SL , et al. Development and validation of a High Performance Liquid Chromatographic method for determination of etoposide in biodegradable polymeric implants. Quím Nova, 2012; 35(6):1239–1243; doi: 10.1590/S0100-40422012000600032

Solano AGR , de Fátima Pereira A , Pinto FC , et al. Development and evaluation of sustained-release etoposide-loaded poly(ε-caprolactone) implants. AAPS PharmSciTech, 2013; 14(2):890–900; doi: 10.1208/s12249-013-9977-6

Solano AGR , de Fátima Pereira A , de Faria LGA , et al. Etoposide-Loaded poly(lactic-co-glycolic acid) intravitreal implants: In vitro and in vivo evaluation. AAPS PharmSciTech, 2018; 19(4):1652–1661; doi: 10.1208/s12249-018-0978-3

Soares DCF , de Paula Oliveira DC , Barcelos LS , et al. Antiangiogenic activity of PLGA-Lupeol implants for potential intravitreal applications. Biomed Pharmacother, 2017; 92:394–402; doi: 10.1016/j.biopha.2017.05.093

Toledo CR , Pereira VV , Ferreira GA , et al. PLGA-corosolic acid implants for potential application in ocular neovascularization diseases. Braz J Pharm Sci, 2020; 56:e18484; doi: 10.1590/s2175-97902019000418484

Vieira LC , Moreira CPS , Castro BFM , et al. Rosmarinic acid intravitreal implants: A new therapeutic approach for ocular neovascularization. Planta Med, 2020; 86(17):1286–1297; doi: 10.1055/a-1223-2525

Toledo CR , Pereira VV , Duarte LP , et al. Anti-angiogenic activity and safety of intraocular application of triterpenes. Doc Ophthalmol, 2021; 143(3):259–270; doi: 10.1007/s10633-021-09841-z

Ozgonul C , Besirli CG . Recent development in the diagnosis and treatment of ocular toxoplasmosis. Ophthalmic Res, 2017; 57(1):1–12; doi: 10.1159/000449169

Melo LA , Paiva MRB , Fernandes-Cunha GM , et al. Clinical outcomes of intravitreal treatment for ocular toxoplasmosis: Systematic review and meta-analysis. Rev Soc Bras Med Trop, 2023; 56:e05522022; doi: 10.1590/0037-8682-0552-2022

Fernandes-Cunha GM , Gouvea DR , de Oliveira GF , et al. Development of a method to quantify clindamycin in vitreous humor of rabbits’ eyes by UPLC-MS/MS: Application to a comparative pharmacokinetic study and in vivo ocular biocompatibility evaluation. J Pharm Biomed Anal, 2015; 102:346–352; doi: 10.1016/j.jpba.2014.08.023

Fernandes-Cunha GM , Rezende CM , Mussel WN , et al. Anti-Toxoplasma activity and impact evaluation of lyophilization, hot molding process, and gamma-irradiation techniques on CLH-PLGA intravitreal implants. J Mater Sci Mater Med, 2016; 27(1):10; doi: 10.1007/s10856-015-5621-1

Fernandes-Cunha GM , Fialho SL , Silva GR , et al. Ocular safety of intravitreal clindamycin hydrochloride released by PLGA implants. Pharm Res, 2017; 34(5):1083–1092; doi: 10.1007/s11095-017-2118-2

Jorge R , Coelho IN , Silva-Cunha A , et al. Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis. Am J Ophthalmol Case Rep, 2021; 22:101093; doi: 10.1016/j.ajoc.2021.101093

Fialho SL , Souza PAF , Fulgêncio GO , et al. In vivo release and retinal safety of intravitreal implants of thalidomide in rabbit eyes and antiangiogenic effect on the chorioallantoic membrane. J Drug Target, 2013; 21(9):837–845; doi: 10.3109/1061186X.2013.829074

Silva GR , Almeida APR , Fernandes-Cunha GM , et al. Safety and in vivo release of fluconazole-loaded implants in rabbits’ eyes. J Drug Deliv Sci Technol, 2016; 35:323–326; doi: 10.1016/j.jddst.2016.08.009

Resende AFC , Pereira AF , Moreira TP , et al. PLGA Implants containing vancomycin and dexamethasone: Development, characterization and bactericidal effects. Pharmazie, 2016; 71(8):439–446; doi: 10.1691/ph.2016.6009

Jorge R , Villela IF , Fernandes C , et al. Intravitreal acetazolamide implant for pseudophakic cystoid macular edema. Doc Ophthalmol, 2023; 147(1):71–75; doi: 10.1007/s10633-023-09939-6

Silva GR , Fialho SL , Siqueira RC , et al. Implants as drug delivery devices for the treatment of eye diseases. Braz J Pharm Sci, 2010; 46(3):585–595; doi: 10.1590/S1984-82502010000300024

Arribada RG , Behar-Cohen F , de Barros ALB , et al. The use of polymer blends in the treatment of ocular diseases. Pharmaceutics, 2022; 14(7):1431; doi: 10.3390/pharmaceutics14071431

Fialho SL , Behar-Cohen F , Silva-Cunha A . Dexamethasone-loaded poly(epsilon-caprolactone) intravitreal implants: A pilot study. Eur J Pharm Biopharm, 2008; 68(3):637–646; doi: 10.1016/j.ejpb.2007.08.004

Silva-Cunha A , Fialho SL , Naud MC , et al. Poly-epsilon-caprolactone intravitreous devices: An in vivo study. Invest Ophthalmol Vis Sci, 2009; 50(5):2312–2318; doi: 10.1167/iovs.08-2969

Silva GR , Silva-Cunha A , Ayres E , et al. Effect of the macromolecular architecture of biodegradable polyurethanes on the controlled delivery of ocular drugs. J Mater Sci Mater Med, 2009; 20(2):481–487; doi: 10.1007/s10856-008-3607-y

Silva GR , Ayres E , Orefice RL , et al. Controlled release of dexamethasone acetate from biodegradable and biocompatible polyurethane and polyurethane nanocomposite. J Drug Target, 2009; 17(5):374–383; doi: 10.1080/10611860902839510

Silva GR , Silva-Cunha A , Behar-Cohen F , et al. Biodegradation of polyurethanes and nanocomposites to non-cytotoxic degradation products. Polym Degrad Stab, 2010; 95(4):491–499; doi: 10.1016/j.polymdegradstab.2010.01.001

Moura SA , Lima LD , Andrade SP , et al. Local drug delivery system: Inhibition of inflammatory angiogenesis in a murine sponge model by dexamethasone-loaded polyurethane implants. J Pharm Sci, 2011; 100(7):2886–2895; doi: 10.1002/jps.22497

Silva GR , Silva-Cunha A , Behar-Cohen F , et al. Biodegradable polyurethane nanocomposites containing dexamethasone for ocular route. Mater Sci Eng C, 2011; 31(2):414–422; doi: 10.1016/j.msec.2010.10.019

Pinto FC , Silva-Cunha A , Oréfice RL , et al. Controlled release of triamcinolone acetonide from polyurethane implantable devices: Application for inhibition of inflammatory-angiogenesis. J Mater Sci Mater Med, 2012; 23(6):1431–1445; doi: 10.1007/s10856-012-4615-5

Barbosa Saliba J , Vieira L , Fernandes-Cunha GM , et al. Anti-Inflammatory effect of dexamethasone controlled released from anterior suprachoroidal polyurethane implants on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci, 2016; 57(4):1671–1679; doi: 10.1167/iovs.15-18127

Silva GR , Lima TH , Oréfice RL , et al. In vitro and in vivo ocular biocompatibility of electrospun poly(ɛ-caprolactone) nanofibers. Eur J Pharm Sci, 2015; 73:9–19; doi: 10.1016/j.ejps.2015.03.003

de Souza SOL , Guerra MCA , Heneine LGD , et al. Biodegradable core-shell electrospun nanofibers containing bevacizumab to treat age-related macular degeneration. J Mater Sci Mater Med, 2018; 29(11):173; doi: 10.1007/s10856-018-6187-5

Silva GR , Lima TH , Fernandes-Cunha GM , et al. Ocular biocompatibility of dexamethasone acetate loaded poly(ɛ-caprolactone) nanofibers. Eur J Pharm Biopharm, 2019; 142:20–30; doi: 10.1016/j.ejpb.2019.05.010

Guerra MCA , Neto JT , Gomes MG , et al. Nanofiber-coated implants: Development and safety after intravitreal application in rabbits. Int J Pharm, 2023; 636:122809; doi: 10.1016/j.ijpharm.2023.122809

Kapoor KG , Wagner MG , Wagner AL . The sustained-release dexamethasone implant: Expanding indications in vitreoretinal disease. Semin Ophthalmol, 2015; 30(5–6):475–481; doi: 10.3109/08820538.2014.889179

Zeng S , Liu XL . A review of ten years of experience using dexamethasone intravitreal implants (Ozurdex) for uveitis. Eur Rev Med Pharmacol Sci, 2023; 27(5):1743–1758; doi: 10.26355/eurrev_202303_31535

Morrison PW , Khutoryanskiy VV . Advances in ophthalmic drug delivery. Ther Deliv, 2014; 5(12):1297–1315; doi: 10.4155/tde.14.75

Chen H . Recent developments in ocular drug delivery. J Drug Target, 2015; 23(7–8):597–604; doi: 10.3109/1061186X.2015.1052073

Bansal P , Garg S , Sharma Y , et al. Posterior segment drug delivery devices: Current and novel therapies in development. J Ocul Pharmacol Ther, 2016; 32(3):135–144; doi: 10.1089/jop.2015.0133

Kaji H , Nagai N , Nishizawa M , et al. Drug delivery devices for retinal diseases. Adv Drug Deliv Rev, 2018; 128:148–157; doi: 10.1016/j.addr.2017.07.002

Nayak K , Misra M . A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother, 2018; 107:1564–1582; doi: 10.1016/j.biopha.2018.08.138

García-Estrada P , García-Bon MA , López-Naranjo EJ , et al. Polymeric implants for the treatment of intraocular eye diseases: Trends in biodegradable and non-biodegradable materials. Pharmaceutics, 2021; 13(5):701; doi: 10.3390/pharmaceutics13050701